| HUMAN-TRIAL | evidence | Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care | Semaglutide | Glycemic control · human-rct · n = 12 | — |
| HUMAN-TRIAL | evidence | Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes | Semaglutide | Glycemic control · human-rct · n = 96 | — |
| HUMAN-TRIAL | evidence | AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Semaglutide | Weight & fat loss · human-rct · n = 1000 | — |
| HUMAN-TRIAL | evidence | The Effect of Semaglutide on Bone Health | Semaglutide | Bone & joint health · human-rct · n = 150 | — |
| HUMAN-TRIAL | evidence | 16-week Flexible vs. 8-week Semaglutide Titration | Ozempic | Glycemic control · human-rct · n = 100 | — |
| HUMAN-TRIAL | evidence | Semaglutide and Intestinal Iron Absorption | Semaglutide | Glycemic control · n = 51 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity | Semaglutide | Weight & fat loss · human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) | Semaglutide | human-rct · n = 573 | — |
| HUMAN-TRIAL | evidence | The Effect of Semaglutide on Cardiovascular Markers and Liver Function | Semaglutide | Glycemic control · human-observational · n = 50 | — |
| HUMAN-TRIAL | evidence | Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy | Semaglutide | Weight & fat loss · human-rct · n = 15 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice | Semaglutide | Glycemic control · human-observational · n = 194 | — |
| HUMAN-TRIAL | evidence | A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity | Semaglutide | human-rct · n = 349 | — |
| HUMAN-TRIAL | evidence | A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | Semaglutide | Kidney function · human-rct · n = 465 | — |
| HUMAN-TRIAL | evidence | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | Semaglutide | Glycemic control · human-rct · n = 1250 | — |
| HUMAN-TRIAL | evidence | Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy | Wegovy | n = 20 | — |
| HUMAN-TRIAL | evidence | Sit Less, Interact and Move More (SLIMM) 2 Study | Semaglutide | Weight & fat loss · human-rct · n = 156 | — |
| HUMAN-TRIAL | evidence | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise | Semaglutide | Glycemic control · human-rct · n = 189 | — |
| HUMAN-TRIAL | evidence | A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese | Semaglutide | Weight & fat loss · human-rct · n = 88 | — |
| HUMAN-TRIAL | evidence | A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 9651 | — |
| HUMAN-TRIAL | evidence | Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects | Semaglutide | Glycemic control · human-rct · n = 161 | — |
| HUMAN-TRIAL | evidence | Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes | Ozempic | Glycemic control · human-rct · n = 50 | — |
| HUMAN-TRIAL | evidence | Bariatric Surgery vs. Semaglutide vs. Tirzepatide | Ozempic | Weight & fat loss · human-rct · n = 125 | — |
| HUMAN-TRIAL | evidence | Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1 | Wegovy | Weight & fat loss · human-rct · n = 20 | — |
| HUMAN-TRIAL | evidence | Semaglutide Use in Acute Pulmonary Embolism | Semaglutide | human-observational · n = 18 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY) | Semaglutide | Glycemic control · human-observational · n = 789 | — |
| HUMAN-TRIAL | evidence | The Effects of Semaglutide on Body Composition and Performance in Military Personnel | Semaglutide | Weight & fat loss | — |
| HUMAN-TRIAL | evidence | Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke | Ozempic | human-rct · n = 380 | — |
| HUMAN-TRIAL | evidence | Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2 | Ozempic | Weight & fat loss · human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 243 | — |
| HUMAN-TRIAL | evidence | Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes | Semaglutide | Glycemic control · human-rct · n = 105 | — |
| HUMAN-TRIAL | evidence | Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function | Semaglutide | Glycemic control · human-rct · n = 44 | — |
| HUMAN-TRIAL | evidence | Pharmacogenetics of Response to GLP1R Agonists | Ozempic | n = 600 | — |
| HUMAN-TRIAL | evidence | A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment | Ozempic | Glycemic control · human-observational · n = 304 | — |
| HUMAN-TRIAL | evidence | Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes | Ozempic | human-observational · n = 50 | — |
| HUMAN-TRIAL | evidence | DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies | Semaglutide | Lipid & cardiovascular markers · human-rct · n = 112 | — |
| HUMAN-TRIAL | evidence | PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults | Semaglutide | Weight & fat loss · human-rct · n = 212 | — |
| HUMAN-TRIAL | evidence | STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Semaglutide | Weight & fat loss · human-rct · n = 1961 | — |
| HUMAN-TRIAL | evidence | A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease | Semaglutide | Kidney function · human-rct · n = 125 | — |
| HUMAN-TRIAL | evidence | A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) | Ozempic | Liver health · human-rct · n = 145 | — |
| HUMAN-TRIAL | evidence | A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE) | Semaglutide | Glycemic control · human-rct · n = 1020 | — |
| HUMAN-TRIAL | evidence | Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV | Ozempic | Weight & fat loss · human-rct · n = 80 | — |
| HUMAN-TRIAL | evidence | Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia | Semaglutide | human-rct | — |
| HUMAN-TRIAL | evidence | Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome | Ozempic | human-rct · n = 150 | — |
| HUMAN-TRIAL | evidence | Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function | Semaglutide | human-rct · n = 22 | — |
| HUMAN-TRIAL | evidence | MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial | Semaglutide | Weight & fat loss · human-rct · n = 151 | — |
| HUMAN-TRIAL | evidence | A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity | Wegovy | Weight & fat loss · human-rct · n = 40 | — |
| HUMAN-TRIAL | evidence | A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation | Wegovy | Weight & fat loss · human-rct · n = 1005 | — |
| HUMAN-TRIAL | evidence | Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus | Semaglutide | Glycemic control · human-observational · n = 212 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS) | Semaglutide | Glycemic control · human-observational · n = 218 | — |
| HUMAN-TRIAL | evidence | Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity. | Semaglutide | Weight & fat loss · human-rct · n = 375 | — |